Clinical trials: Moderate to Severe Asthma
Asthma
Nebulized Magnesium Sulfate in Pediatric Asthma
Nebulized Magnesium Sulfate has been shown to be of benefit in adults with acute asthma exacerbations, though limited work has been done in the pediatric population.
- Trial name
- NCT00522444
- Testing
- Nebulized Magnesium Sulfate, Nebulized normal saline
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Asthma (Part 1), COPD (Part 2)
Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects
This is a phase I, randomised, placebo-controlled 2-part study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8871 delivered by inhalation, in asthmatic and chronic obstructive pulmonary disease…
- Trial name
- NCT02573155
- Testing
- Dose 1, AZD8871 50 μg (Part 1), Dose 2, AZD8871 100 μg (Part 1), Dose 3, AZD8871 300 μg (Part 1)
- Where
- 2 sites in United Kingdom
- Volunteers
- 134 people
- Sponsor
- AstraZeneca
Asthma
Evaluating Effects of Curcumin in Moderate to Severe Asthmatics
The purpose of this investigator-initiated study is to evaluate the effects of oral curcumin supplementation versus placebo in adult patients with moderate to severe asthma.
- Trial name
- NCT04353310
- Testing
- Curcumin
- Sponsor
- Loma Linda University
Lung Disease
Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair
The purpose of this study is to study the effects of Xolair using non-invasive techniques from the expired gas of patients with moderate to severe allergic asthma.
- Trial name
- NCT00139152
- Testing
- Xolair
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Creighton University
Asthma
Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)
This study is multicenter, double-blinded parallel group design, where participants with moderate to severe asthma with AFAD will be enrolled.
- Trial name
- NCT03393806
- Testing
- GSK3772847
- Where
- 18 sites in France, Netherlands and 2 more
- Volunteers
- 17 people
- Sponsor
- GlaxoSmithKline
Asthma
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
The purpose of this study is to provide safety and tolerability, pharmacokinetics and immunogenicity data for multiple CSJ117 doses inhaled once daily compared with placebo, in adult asthma participants treated with medium or…
- Trial name
- NCT04946318
- Testing
- CSJ117
- Where
- 58 sites in United States, Argentina and 12 more
- Volunteers
- 136 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study of Omalizumab in Moderate to Severe Bronchial Asthma
This study will evaluate the safety and efficacy of omalizumab up to 16 weeks in adult patients with moderate to severe bronchial asthma.
- Trial name
- NCT00232050
- Testing
- Omalizumab
- Volunteers
- 327 people
- Sponsor
- Novartis
Asthma
A Randomized, Double-Blind, Placebo-Controlled Phase Ib Study of Multiple Ascending Doses of EB070 Injection in Adults With Moderate-to-Severe Asthma
This is a multicenter, randomized, double-blind, placebo-controlled, multiple-dose, dose-escalation Phase Ib clinical study designed to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD)…
- Trial name
- NCT07886710
- Testing
- EB070
- Volunteers
- 20 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Asthma
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
Single center, randomized, placebo- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or placebo.
- Trial name
- NCT04743791
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Sally E. Wenzel MD
Asthma
An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma
The study proposes to evaluate the safety and efficacy of PF-03715455 in moderate to severe asthma when added to standard of care and during staged withdrawal of background therapy.
- Trial name
- NCT02219048
- Testing
- PF-03715455
- Where
- 28 sites in United States
- Volunteers
- 51 people
- Sponsor
- Pfizer
Asthma in Children
BiPAP in Pediatric Moderate to Severe Asthma Randomized Control Trial
The goal of this clinical trial is to study if starting bi-level positive airway pressure (BiPAP), a mask that gives pressure to the lungs, works well for children in the emergency department with moderate to severe asthma…
- Trial name
- NCT05848115
- Testing
- Bi-level Positive Airway Pressure
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of Colorado, Denver
Asthma
Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma
This study will evaluate the pharmacokinetic (PK) profile of a single subcutaneous (SC) dose of tezepelumab in children aged ≥ 5 to 11 years with asthma.
- Trial name
- TRAILHEAD (NCT04673630)
- Testing
- Tezepelumab
- Where
- 6 sites in Hungary, South Africa and 1 more
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Moderate to Severe Asthma
A Study of CM310 in Subjects With Moderate to Severe Asthma
This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅱ/Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe…
- Trial name
- NCT05761028
- Testing
- CM310
- Where
- China
- Volunteers
- 600 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Bronchial Asthma
A Study to Assess the Efficacy of Inhaled Corticosteroid (ICS) Therapy in Moderate-Severe Bronchial Asthma
The purpose of this study is to investigate/assess the treatment of moderate to severe asthmatics with inhaled corticosteroid.
- Trial name
- NCT00411567
- Testing
- inhaled corticosteroid therapy
- Where
- Germany
- Volunteers
- 26 people
- Sponsor
- Novartis
Eosinophilic Asthma
A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma
1. Eosinophilic asthma, a type 2 immune disorder, often involves the excessive production of type 2 cytokines. 2. Excessive Type 2 cytokines lead to chronic inflammation, airway hyperresponsiveness, and airflow obstruction. 3.
- Trial name
- NCT07250594
- Testing
- AD17002, Formulation buffer
- Where
- Taiwan
- Volunteers
- 126 people
- Sponsor
- Advagene Biopharma Co. Ltd.
Moderate to Severe Asthma
CHEST: A Collaboration With Community HEalth Centers to Implement SmarT for Asthma
Purpose: This study aims to improve asthma care by helping clinicians at community health centers prescribe a guideline-recommended treatment called SMART (Single Maintenance and Reliever Therapy).
- Trial name
- CHEST (NCT07241117)
- Testing
- Implementation bundle
- Where
- 7 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Washington University School of Medicine
Moderate-to-severe Allergic Asthma
A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma
This study will assess the effect of omalizumab on exercise capacity, physical activity, and sleep quality after 24 weeks of treatment in participants with moderate to severe allergic asthma.
- Trial name
- EDURO (NCT04195958)
- Testing
- Omalizumab
- Where
- 12 sites in United States
- Volunteers
- 3 people
- Sponsor
- Genentech, Inc.
Asthma Bronchiale
Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma
Open, parallel group design. The study has a screening phase and a 12 week treatment phase. Subjects will be randomised to treatment in a 1:1 ration.
- Trial name
- NCT00476073
- Testing
- FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)
- Where
- United Kingdom
- Volunteers
- 228 people
- Sponsor
- Mundipharma Research Limited
Asthma
A Study of HB0056 in Adult Participants With Moderate to Severe Asthma
The goal of this clinical trial is to learn if drug HB0056 works to treat severe asthma in adults. It will also learn about the safety of drugHB0056.
- Trial name
- NCT07899996
- Testing
- HB0056
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Moderate to Severe Asthma
A Study of CM326 in Subjects With Moderate to Severe Asthma
This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅱ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to severe…
- Trial name
- NCT05774340
- Testing
- CM326
- Where
- China
- Volunteers
- 207 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.